Permanent 125I‐seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results
Authors: Borchers Holger , Kirschner‐Hermanns Ruth , Brehmer Bernhard , Tietze Lothar , Reineke Thorsten , Pinkawa Michael , Eble Michael J. , Jakse Gerhard 
Published: October 2004

OBJECTIVE

To assess the quality of life in patients with prostate cancer after permanent brachytherapy (BT) or radical perineal prostatectomy (RP).

PATIENTS AND METHODS

The American Brachytherapy Society recommends the permanent implantation of radioactive seeds as a monotherapy for patients with T1–T2aN0M0 prostate cancer and a prostate‐specific antigen (PSA) level of ≤ 10 ng/mL, a Gleason score of <7 and a prostate volume of <60 mL. Using these criteria, 132 patients with low‐risk prostate cancer were selected; 52 had BT with 125I‐seed implantation, 38 had RP with unilateral nerve‐sparing (RP + NS) and 42 extended RP (RP group). Only patients with unilateral tumour on biopsy were considered. Before therapy and 6, 12 and 24 months afterward, patients completed questionnaires to assess perceived health and function. PSA relapse was diagnosed with a PSA of >0.1 ng/mL for patients in the RP groups, and three consecutive PSA increases for those after BT.

RESULTS

Extraprostatic tumours were found in 18% of specimens taken during RP, and bilateral tumours in 63% of patients. After a mean follow‐up of 27 months, there was PSA relapse in two of the 80 patients in the RP and RP + NS groups, and six of the 52 patients in the BT group; a significant difference, with a hazard ratio of 5.2. The acute morbidity was low in all groups. At 1 year, more than two incontinence pads were used by 5% of patients after RP and by 4% after BT. Similarly, at 1 year 15% of patients after RP and 13% after BT were bothered by urinary incontinence. Newly‐developed fecal soiling was reported by 4%, 5% and 11% of the RP, RP + NS and BT groups respectively; none of the patients after RP and 4% after BT were bothered by this symptom. The duration and stiffness of erection was assessed after 1 year and reported to be equal or slightly decreased by a third after RP + NS and 38% after BT. Taking a 5–10 point difference as clinically relevant, role, emotional and social functioning were improved considerably after RP + NS than after BT, but sexual activity was impaired significantly after RP + NS than after BT.

CONCLUSIONS

Both therapies showed typical acute and late morbidity; the most bothersome late symptoms were urinary incontinence for patients after RP and fecal soiling after BT. Sexual function was impaired significantly in patients who were potent before RP + NS, whereas after BT men reported only a minor change in sexual performance at 1 year. Tumour control after a median follow‐up of 27 months was better after RP but biochemical recurrence may still occur after ≥ 5 years; therefore the present results are not mature enough and there were too few patients to provide a more definitive statement. As ≈ 18% of patients considered to be appropriate candidates for BT had tumours extending beyond the prostate capsule or invading the seminal vesicles, nomograms are needed for more accurate information before therapy.